Differential methylation profile of ovarian cancer in tissues and plasma

Journal of Molecular Diagnostics

Volumn 11, Issue 1, 2009, Pages 60-65

  Melnikov, Anatoliy ^a   Scholtens, Denise ^a   Godwin, Andrew ^b   Levenson, Victor ^a,c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; ARTICLE; BAYES THEOREM; CANCER SCREENING; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; OVARY; OVARY CANCER; PLASMA; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TUMOR GENE;

ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; DNA; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 58849140824     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.080072     Document Type: Article

References (28)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30
2. Jacobs I, Bast RC, Jr: The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989, 4:1-12
3. Bast RC, Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68:1331-1337
4. Munkarah A, Chatterjee M, Tainsky MA: Update on ovarian cancer screening. Curr Opin Obstet Gynecol 2007, 19:22-26
5. Bast RC, Jr: Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003, 21:200S-205S
6. Bast RC, Jr., Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y: Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007, 174:91-100
7. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ: Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. Bjog 2000, 107:165-169
8. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005, 192:1214-1221; discussion 1221-1212
9. Olivier Rl, Lubsen-Brandsma MA, Verhoef S, van Beurden M: CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006, 100:20-26
10. Bast RC, Jr., Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K: New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005, 15 Suppl 3:274-281
11. Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY. Lin YG, Merritt WM, Landen CN, Jr., Lu C, Gershenson DM, Simpson JL, Sood AK: Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 2006, 5:1369-1374
12. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D. Yu H: Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006, 107:299-308
13. Melnikov AA, Gartenhaus RB, Levenson AS, Motchoulskaia NA, Levenson Chernokhvostov VV: MSRE-PCR for analysis of gene-specific DNA methylation. Nucleic Acids Res 2005, 33:e93
14. Melnikov AA, Scholtens DM, Wiley EL, Khan SA, Levenson VV: Array-based multiplex analysis of DNA methylation in breast cancer tissues. J Mol Diagn 2008, 10:93-101
15. Scholtens D, von Heydebreck A: Analysis of differential gene expression. In Studies in Bioinformatics and Computational Biology Solutions using R and Bioconductor, H.W. Gentleman R, Irizarry R, Dudoit S, Editor. 2005, Springer: Berlin. p. 229-248
16. Model F, Adorjan P, Olek A, Piepenbrock C: Feature selection for DNA methylation based cancer classification. Bioinformatics 2001, 17 Suppl 1:S157-S164
17. Domingos P, Pazzani MJ: On the optimality of the simple Bayesian classifier under zero-one loss. Machine Learning 1997, 29:103-130
18. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S. Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, lacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J: Bioconductor: open software development for computational biology and bioinformatics Genome Biol 2004, 5:R80
19. Strathdee G, Appleton K, llland M, Millan DW. Sargent J, Paul J, Brown R: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001, 158:1121-1127
20. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E. Edelson Ml, Bergman C, Ehya H, Eisenberg BL, Cairns P: Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum. plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004, 64:6476-6481
21. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004. 10:4420-4426
22. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE: Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002, 94:61-67
23. Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA: High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 2005, 159:114-122
24. Bryan EJ, Jokubaitis VJ, Chamberlain NL, Baxter SW, Dawson E, Choong DY, Campbell IG: Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int J Cancer 2002, 102:137-141
25. Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, Huang H,
26. Hartmann LC, Kaufmann SH, Smith Dl: Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res 2001, 61:4258-4265
27. Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, Mita H, Imai K, Tokino T, Kudo R: Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 2004, 10:2000-2006
28. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M: Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res 2002, 22:3191-3196